Close Menu
    Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Antimicrobial Resistance

    Is it a Bacterial or Viral Infection? Novel MeMed Rapid Test Receives FDA Clearance

    By Global Biodefense StaffSeptember 24, 2021
    The MeMed Key diagnostic tool recently received full FDA licensure. Courtesy photo: Defense Threat Reduction Agency's Chemical and Biological Technologies Department
    Share
    Facebook LinkedIn Reddit Email

    Novel host response protein signature technology can rapidly distinguish between bacterial and viral infections to speed treatment decisions and combat the growing threat of Antimicrobial Resistance.

    The MeMed Key diagnostic tool recently received full FDA licensure after four years of research, development, and investments by Defense Threat Reduction Agency’s (DTRA) Chemical and Biological Technologies Department in its role as the Joint Science and Technology Office (JSTO) for the Chemical and Biological Defense Program.

    Each year in the United States, about three million Americans fall ill to antibiotic-resistant infections, and 35,000 die from those illnesses. To definitively answer whether an infection is bacterial versus viral, DTRA-JSTO has been investing in the MeMed Key program efforts.

    Utilizing MeMed Key, patients will be able to visit their local health clinics and – in as little as 15 minutes with blood from a finger prick – be able to identify whether their symptoms are due to an active bacterial or viral infection.

    MeMed Key is a first of its kind immunoassay platform, that opens the way to measuring multiple proteins with central lab performance at the point-of-need.

    “This new technology will better position us to identify emerging threats and reduce the use of unnecessary medical countermeasures such as antibiotics,” said Richard Schoske, Ph.D., chief for DTRA-JSTO’s Diagnostics and Detection efforts.

    DTRA-JSTO invested $9.2 million in 2017 to fund the completion of MeMed’s pioneering point of care platform for distinguishing bacterial from viral infections. In 2018, the DOD’s Congressionally Directed Medical Research Programs (CDMRP) awarded the company an additional $4.1 million to support transition of the company’s prototype ImmunoPoC point-of-care (POC) blood-testing platform toward a final product, including transfer to manufacturing and implementation of cloud connectivity.

    Antimicrobials Editor Pick POC Diagnostics
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleMassive Numbers of New COVID–19 Infections, Not Vaccines, Main Driver of New Coronavirus Variants
    Next Article New Treatments for COVID-19 May Stave Off the Worst Effects of the Virus

    Related Stories

    First Light Diagnostics Receives FDA Clearance for Rapid Anthrax Test

    December 5, 2023

    Chlorine Exposure Biomarkers in a Large Animal Model

    December 5, 2023

    ARPA-H Announces New Tiered Proposal Submission System to Reduce Applicant Barriers

    December 5, 2023

    Needle-Free Vaccine Patch Against Zika Virus

    December 2, 2023
    News Scan

    Biodefense Headlines – 30 November 2023

    News Scan November 30, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include the largest ever outbreak of mpox in the DRC; launch of National Wastewater Surveillance Program dashboard; low uptake of COVID-19 boosters and flu vaccines;…

    Upcoming Events

    Mar 12
    Hybrid Hybrid Event
    March 12, 2024 - March 17, 2024

    2024 Fungal Genetics Conference

    Mar 21
    March 21, 2024 - March 23, 2024

    ASPPH 2024 Annual Meeting

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    News on pathogens and preparedness for public health emergencies

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.

    Global Biodefense places cookies on your device to enable the best user experience. By using our website, you agree to placement of these cookies. To learn more, read our Privacy Policy.OKPrivacy Policy